Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006350 · ClinicalTrials.gov registry record · Phase 2
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006350: Completed Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT00006350 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006350, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation from a brother or sister may be effective treatment for hematologic cancer. Sometimes the transplanted cells can be rejected by the body's tissue. Mycophenolate mofetil, tacrolimus, and donor white blood cells may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of mycophenolate mofetil, tacrolimus, daclizumab, and donor peripheral stem cell transplantation in treating patients who have hematologic cancer.
Interventions
- DRUG tacrolimus
- PROCEDURE peripheral blood stem cell transplantation
- DRUG mycophenolate mofetil
- BIOLOGICAL therapeutic allogeneic lymphocytes
- BIOLOGICAL daclizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-01 |
| Est. Completion | 2001-11 |
| Phase | Phase 2 |
What the finished NCT00006350 record still lists
NCT00006350 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which tacrolimus is the first listed.
NCT00006350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006350 about?
NCT00006350 is a clinical study titled "Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation from a brother or sister may be effective treatment for hematologic cancer. Sometimes the tra...
What is the current status of trial NCT00006350?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-01. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00006350?
The interventions under investigation include: tacrolimus (DRUG), peripheral blood stem cell transplantation (PROCEDURE), mycophenolate mofetil (DRUG), therapeutic allogeneic lymphocytes (BIOLOGICAL), daclizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006350?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia